Kliniken der Stadt Koeln gGmbH

The department is evaluating new oral agents for Idiopathic Pulmonary Fibrosis, with the goal of slowing disease progression and preserving lung capacity.

• Oral MBS2320 assessment in IPF
• Impact on forced vital capacity
• Safety profile compared with placebo

Research is conducted at Kliniken der Stadt Koeln gGmbH in Cologne, Germany, involving 26 investigators and a total of five active trials.

A focused study on Neurotrophic Keratopathy examines a novel ophthalmic solution designed to promote corneal healing and maintain visual function.

• RGN-259 ophthalmic solution safety and efficacy
• Double‑blind placebo‑controlled design
• Central review of corneal outcomes

The trial takes place within the Department of Anesthesiology and Critical Care Medicine at Merheim Medical Center, supporting multidisciplinary patient care.

Ongoing investigations target Resectable Stage II‑IIIB Non‑small cell lung cancer and Unresectable Pleural Mesothelioma, testing innovative immunotherapy‑chemo combinations to improve overall survival.

• Volrustomig with carboplatin/pemetrexed versus standard of care
• Pre‑ and postoperative nivolumab integration
• Event‑free survival assessment by blinded review

These oncology trials are coordinated at the Merheim campus, leveraging the expertise of 26 investigators across the institution.

A critical‑care trial evaluates high‑dose intravenous vitamin C for severe burn patients, aiming to reduce persistent organ dysfunction and mortality when added to standard therapy.

• High‑dose vitamin C infusion protocol
• 28‑day composite outcome of organ dysfunction and mortality
• Placebo‑controlled randomized design

Conducted at the Merheim Medical Center, the study benefits from the department’s extensive experience in managing complex trauma cases.

While current trials emphasize oncology and respiratory disease, the department retains strong capabilities in treating infection‑related complications in critical care, laying groundwork for future antimicrobial studies.

• Critical‑care infection monitoring
• Integration of antimicrobial guidelines
• Readiness for future bacterial/mycotic trial enrollment

The facility’s comprehensive infection management program supports patient safety and positions the site for upcoming research initiatives.